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Abstract: Background
Scotland introduced PCV7 and PCV13 immunisation in young children in 2006 and
2010 respectively. One recent study from the United States reported a decrease in
hospitalisation rates for all-cause pneumonia most notably in adults older than 75
years of age following PCV7 introduction in the US child population. We aimed to
examine the effect of PCV7 and PCV13 on hospitalisation rates for all-cause
pneumonia across all age groups in Scotland.
Methods
We linked hospital records and death certification datasets for the entire Scottish
population for the period 2000 to 2012. We included all cases where the primary /
secondary diagnosis was pneumonia. Differences in hospital admission rates for
pneumonia by age group were calculated using the difference in average annual rates
for each period.
Results
We estimated that all-cause pneumonia hospitalisation rates in children <2 years
decreased by about 30% in the post-PCV-13 period compared with the pre-PCV
period. However, in adults aged 75-84 years and ≥85 years, all-cause pneumonia
hospitalisation rates increased by 63% and 46 % respectively in the post-PCV 13
period compared to the pre-PCV period. This resulted in an additional 7000
hospitalisations across all age groups in Scotland in 2012 about half of which were in
adults >75 years. At the same time, the median length of hospital stay decreased by a
third in children <2 years and by about 20% in adults >75 years in the post-PCV13
period compared to the pre-PCV period. Additionally, there was an 11% reduction in
deaths due to all-cause pneumonia, and 30% reduction in pneumococcal
hospitalisations across all age groups in the post-PCV13 period compared with pre-
PCV period.
Interpretation
The modest and sustained decline in the rates of hospitalisation for all-cause
pneumonia in children and the reduction in proportion of pneumonia hospitalisations in
children coded as pneumococcal disease in the post-PCV period should alleviate
concerns that pneumococcal serotype replacement may have resulted in an increased
pneumonia burden in this age group. The indirect impact of child PCV immunisation in
those not vaccinated (in terms of reduction in all-cause pneumonia hospitalisations in
the elderly) has not been seen in Scotland. Our results are likely to be confounded by
changes in clinical coding and healthcare practices over the same period and illustrate
that health care planners cannot, with confidence, predict indirect PCV vaccine impacts
on hospitalisations. IPD surveillance across all age groups is needed to assess the
indirect effects of PCV in the community.
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Abstract 1 
Background 2 
Scotland introduced PCV7 and PCV13 immunisation in young children in 2006 and 2010 respectively. 3 
One recent study from the United States reported a decrease in hospitalisation rates for all-cause 4 
pneumonia most notably in adults older than 75 years of age following PCV7 introduction in the US 5 
child population. We aimed to examine the effect of PCV7 and PCV13 on hospitalisation rates for all-6 
cause pneumonia across all age groups in Scotland. 7 
Methods 8 
We linked hospital records and death certification datasets for the entire Scottish population for the 9 
period 2000 to 2012. We included all cases where the primary / secondary diagnosis was 10 
pneumonia. Differences in hospital admission rates for pneumonia by age group were calculated 11 
using the difference in average annual rates for each period. 12 
Results 13 
We estimated that all-cause pneumonia hospitalisation rates in children <2 years decreased by 14 
about 30% in the post-PCV-13 period compared with the pre-PCV period. However, in adults aged 15 
75-84 years and ≥85 years, all-cause pneumonia hospitalisation rates increased by 63% and 46 % 16 
respectively in the post-PCV 13 period compared to the pre-PCV period. This resulted in an 17 
additional 7000 hospitalisations across all age groups in Scotland in 2012 about half of which were in 18 
adults >75 years. At the same time, the median length of hospital stay decreased by a third in 19 
children <2 years and by about 20% in adults >75 years in the post-PCV13 period compared to the 20 
pre-PCV period. Additionally, there was an 11% reduction in deaths due to all-cause pneumonia, and 21 
30% reduction in pneumococcal hospitalisations across all age groups in the post-PCV13 period 22 
compared with pre-PCV period.  23 
Interpretation 24 
The modest and sustained decline in the rates of hospitalisation for all-cause pneumonia in children 25 
and the reduction in proportion of pneumonia hospitalisations in children coded as pneumococcal 26 
disease in the post-PCV period should alleviate concerns that pneumococcal serotype replacement 27 
may have resulted in an increased pneumonia burden in this age group. The indirect impact of child 28 
PCV immunisation in those not vaccinated (in terms of reduction in all-cause pneumonia 29 
hospitalisations in the elderly) has not been seen in Scotland. Our results are likely to be confounded 30 
by changes in clinical coding and healthcare practices over the same period and illustrate that health 31 
care planners cannot, with confidence, predict indirect PCV vaccine impacts on hospitalisations. IPD 32 
surveillance across all age groups is needed to assess the indirect effects of PCV in the community.  33 
Keywords:  34 
pneumococcal conjugate vaccine; indirect effects; all-cause pneumonia hospitalisations; 35 
pneumococcal hospitalisations; pneumonia mortality 36 
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Introduction 1 
Globally, lower respiratory tract infections (primarily pneumonia) were the second leading cause of 2 
morbidity and fourth leading cause of mortality across all age groups in 2013 [1]. The burden of 3 
pneumonia is disproportionately higher in young children and the elderly (above 65 years of age) [2, 4 
3]. In general, mortality due to pneumonia across all ages has declined substantially (22 (95% CI 16 5 
to 30) percent) between 1990 and 2013 [1]. Prior to the introduction of the pneumococcal conjugate 6 
vaccine (PCV) in the US, hospitalisation rates for pneumonia in the elderly (65 to 84 years) increased 7 
by about 20% in the 15 year period between 1988-1990 to 2000-2002 [3]. Similar increases (over a 8 
similar though abbreviated period) have been reported in England, Denmark, and the Netherlands 9 
[4-6]. The increase in this age group has been attributed to an ageing population, increase in the 10 
prevalence of comorbidities, and changes in coding and hospital admission practices [4]. 11 
The prevalence of Streptococcus pneumoniae in adults with community-acquired pneumonia (CAP) 12 
has declined sharply since the advent of antibiotics. Data from Medicare (for year 2009) indicate that 13 
about 7.6% of CAP hospitalisations in the elderly (aged 65 years and above) in the United States can 14 
be attributed to Streptococcus pneumoniae [7]. Therefore, pneumococcal polysaccharide vaccine 15 
(PPV) was introduced in Scotland in the winter of 2003 to persons aged 65 years and above, and high 16 
risk individuals (i.e. those with co-morbidities). Following the introduction of PCV7 into the national 17 
child immunisation schedules in the US and England and Wales, there has been a decrease in the 18 
overall incidence of invasive pneumococcal disease (IPD) across all age groups [8, 9]. PCV7 was 19 
introduced into the Scottish child immunisation schedule in September 2006 at the age of 2 and 4 20 
months with a booster dose at around 13 months. Severe pneumococcal disease (using IPD as a 21 
surrogate) was increasing in Scotland in the period prior to introduction of PCV7 (from 559 cases in 22 
2000 to 753 cases in 2006) [10]. After the introduction of PCV7, and PCV13 later in 2010 (both using 23 
2+1 dose schedule), there has been a decrease in the number of IPD cases in children younger than 5 24 
years (from 753 cases in 2006 to 482 cases in 2012). It was expected that with the increased uptake 25 
of PCV, there would be an increase in the circulating non-vaccine serotypes (NVT) [11, 12]. In the US, 26 
after the introduction of PCV7, there was an increase in disease (across all age groups especially in 27 
young children and elderly) caused by NVT, most notably serotype 19 A [13]. In addition, in 2013, 28 
Griffin and colleagues demonstrated a decrease in hospitalisation rates for all-cause pneumonia 29 
(henceforth referred to as pneumonia) not only in children but also across all age groups, most 30 
notably in adults older than 75 years of age following introduction PCV7 in the US child population 31 
[14]. We aimed to examine the effect of PCV7 and PCV13 on hospitalisation rates for pneumonia 32 
across all age groups in Scotland and examine the generalizability of Griffin and colleagues’ findings. 33 
Methods 34 
Data Sources 35 
Scotland has an excellent health service data system with an ability to perform high quality linkage 36 
(through a unique personal identifier attached to health records – the Community Health Index [CHI] 37 
number) of individual hospitalisation, laboratory and death certification data which permits 38 
individual patient data analysis and follow-up. National Services Scotland is responsible for 39 
maintaining these data and ensuring high data quality, consistency and coverage and appropriate 40 
levels of data governance (http://www.isdscotland.org/). The Scottish Morbidity Record (SMR01) 41 
comprises episode level data on hospital inpatient and day case discharges from acute specialties 42 
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from hospitals in Scotland. The dataset contains patient identifiers such as the CHI number, 1 
demographic details such as postcode together with health record data (episode management 2 
details and general clinical information). These data have been available electronically (for research 3 
purposes) since 1981. Usually, when inpatients and day cases are transferred to another specialty 4 
within the same hospital or are transferred to another hospital, a new record on SMR01 is 5 
generated. However, in this analysis, we used continuous inpatient stay (CIS) data by linking SMR01 6 
episodes for each patient. This created “linked” individual patient histories (which includes transfers 7 
between hospitals, specialties, and consultants). This integrated measure documents the length of 8 
continuous hospital care episodes. Data from SMR01 on hospital admissions for pneumonia, 9 
hospitalisation, discharge diagnosis of pneumococcal pneumonia, readmissions within 14 days, sex, 10 
age, health board area, length of stay; and mortality data from General Register Office of Scotland 11 
(GRO99B) were collected.  12 
Definition of hospitalisation for pneumonia 13 
Hospitalisation for pneumonia was defined in accordance with ICD 10 procedures. CIS data were 14 
selected for inclusion in the study if the patient had a primary diagnosis of pneumonia OR a primary 15 
diagnosis of sepsis, meningitis or empyema, with a diagnosis of pneumonia in any subsequent 16 
diagnostic position. A list of ICD 10 codes used to qualify diagnosis for all-cause pneumonia, 17 
meningitis, empyema, septicemia and pneumococcal pneumonia are detailed in Supplementary 18 
table 1.  We considered hospital readmissions within 14 days of the primary admission as part of the 19 
same event[15].  20 
Statistical analysis 21 
SMR01 data from 2000 through 2012 (epidemiological year July-June) were used as numerator data 22 
in estimating annual hospitalisation rates for pneumonia. We constructed a cohort of patients by 23 
linking hospital records and death certification datasets. We used the following age groups for 24 
analysis: children aged below two years, 2 to 4 years, 5 to 17 years, adults aged 18 to 39 years, 40 to 25 
64 years, 65 to 74 years, 75 to 84 years, and 85 years or older. We stratified the analysis into three 26 
different time periods: 2000 through 2005 were considered as the pre-PCV period; 2006 was treated 27 
as transition year, as this was the year that PCV was introduced nationally and therefore excluded 28 
from the analysis; 2007 through 2009 as the post-PCV7 period; and 2010 through 2012 as the post-29 
PCV13 period (as PCV 13 was introduced nationally in April 2010). We used population by Scottish 30 
NHS Health Board of residence provided by ISD (based on official national census data and 31 
estimates) as population denominator data in the calculation of annual hospital admission rates (by 32 
age group) and reported these per 100,000 persons per year. Differences in hospital admission rates 33 
by age group were calculated using the average annual rates for each period, and the observed and 34 
expected rates were compared. We used these data to derive the percentage difference in relative 35 
rates. Where no data were available for a particular health board (age/sex/year combination), most 36 
frequently seen in the case of the smallest Health Boards, we assumed that there were no cases of 37 
pneumonia, rather than regarding these as missing data. Where the Health Board was given as 38 
“Other”, we considered that these could be due to two reasons: data were missing but the patient 39 
was resident in Scotland; or patient was a resident of another country but was treated in Scotland. 40 
We considered both scenarios in the analysis. 41 
All data analyses were conducted using SPSS V19.0 (IBM, NY, USA) and SAS V9.2 (SAS institute Inc., 42 
NC, USA). 43 
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Results 1 
From 2000 to 2012, there were 153,636 new hospitalisation episodes for pneumonia across 2 
Scotland. In addition to these hospitalisations, there were 4551 readmissions within 14 days of 3 
discharge. Pneumonia was the first listed diagnosis for 97.6% of these hospitalisations. Sepsis was 4 
the first listed diagnosis for 1.9%, and meningitis and empyema the first listed diagnosis each for 5 
0.3% and 0.2% respectively. Prior to the introduction of PCV, we observed a gradual increase in the 6 
rates of pneumonia hospitalisation in children aged below 5 years (Figure 1). A similar pattern was 7 
seen in adults aged over 75 years (Figure 2). Across the twelve year period (2000-2012), the annual 8 
rates of pneumonia hospitalisations were highest in adults aged above 65 years and children aged 9 
below two years (Table 1). In the pre-PCV period, the rates for pneumonia hospitalisation in adults 10 
aged 75 to 84 years and 85 years and above, were approximately 3 and 6.5 fold higher respectively 11 
than those in children aged less than two years. In the post-PCV 7 period, this difference increased 12 
to about 5 and 9 fold respectively; and further increased to about 7 and 13 fold respectively in the 13 
post-PCV 13 period. This pattern was sustained even when data from “other” Health Boards were 14 
excluded (Supplementary figure 1 and 2). 15 
The pneumonia hospitalisation rates in children aged less than 2 years decreased by about 30% in 16 
the post-PCV 13 period compared to the pre-PCV period (Figure 3). Pneumonia hospitalisations in 17 
this age group declined by about 19 percent in the post-PCV7 period (compared to pre-PCV) and by 18 
about 14 percent in the post-PCV13 period (compared to post-PCV7). However, the rates remained 19 
largely unchanged in the age groups 2-39 years. We saw that in the older age groups, the pneumonia 20 
hospitalisation rates increased steadily in the post-PCV period (greater increase post-PCV13 21 
compared to post-PCV7). In adults aged 75 -84 years and 85 years and above, the pneumonia 22 
hospitalisation rates increased by 63 and 46 percent respectively in the post-PCV 13 period 23 
compared to the pre-PCV period (Table 1, Supplementary table 2). This translates to an absolute 24 
increase of about 7000 hospitalisations across all age groups in Scotland in 2012. Half of this increase 25 
was observed in age groups older than 74 years (increase of 2200 and 1300 hospitalisations in the 26 
age group 75-84 years and 85 years and above respectively (Table 2).  27 
We observed that during 2000-2012, the mean and median length of stay (LOS) increased with age 28 
(Supplementary figure 3 and supplementary table 3). The pattern of longer stays (defined as more 29 
than 30 days) is the familiar “hook” pattern with the lowest number being in the 2-4 year age group 30 
and then increasing with age (Supplementary table 4). This pattern is sustained even if a lower 31 
threshold (of stays more than 14 days) is used to define longer hospitalisation. In the post-PCV 13 32 
period, median length of hospital stay decreased by a third in children aged below 2 years and by 22 33 
and 18 percent in the age groups 75-84 years and 85 years and above respectively compared with 34 
the pre-PCV period (Table 1). We also observed that although the distribution of length of stay in 35 
hospital (across all age groups) remained the same in the pre-PCV and post-PCV13 period, there was 36 
a significantly higher proportion of patients with stays longer than 14 days in the former (24.8% vs 37 
20.9%, p<0.001) (supplementary table 5). When the analysis was stratified by age, the pattern of 38 
significantly higher proportion of patients with stays longer than 14 days was seen only in adults 39 
aged over 40 years (Supplementary table 5).  40 
The proportion of pneumonia hospitalisations coded as pneumococcal disease decreased 41 
substantially across all age groups in the post-PCV13 period (Table 1). The most dramatic reduction 42 
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was seen in children aged below 5 years (about a two-thirds reduction) while in the elderly aged 85 1 
years only a one-third reduction was demonstrated. At a population level, we observed 29 (95% CI 2 
22 to 35) percent reduction in pneumococcal admissions across all age groups in Scotland in the 3 
post-PCV13 period compared to pre-PCV period. However, this varied by age group -while there was 4 
a 70% reduction in pneumococcal hospitalisations in children aged below 5 years in the post-PCV13 5 
period compared to pre-PCV period, older age groups experienced a  more modest reduction (21 6 
and 25 percent in those 65-74 years and 75 years and above respectively) (Supplementary table 6).  7 
We observed a substantial reduction in the proportion of deaths due to pneumonia (as a primary 8 
cause) across all age groups in the post-PCV13 period when compared to pre-PCV period. In elderly 9 
patients aged 75-84 and 85 years and above there was a decrease of about 53% and 40%  10 
respectively (Table 1 ). This pattern was sustained when deaths from pneumonia were defined more 11 
broadly and included all deaths in which pneumonia was mentioned on the death certificate but was 12 
not recorded as the underlying cause of death (Supplementary table 7). At a population level, there 13 
was an overall 11% reduction in deaths in post-PCV13 period compared to pre-PCV period, with a 19 14 
and 12 percent reduction in those aged 65-74 years and 75 years and above respectively 15 
(supplementary table 8). We also observed a 7 percent reduction in pneumococcal deaths across all 16 
age groups with an 18 and 12 percent reduction in the 65-74 years and 75 years and above age 17 
groups respectively (Supplementary table 9).  18 
Discussion 19 
This is the first national study to report the impact of a child PCV immunisation programme on 20 
pneumonia hospitalisations across all age groups. Our results are based on a Scottish national 21 
dataset for a 12 year period (2000-2012). We observed modest and sustained declines in the 22 
childhood hospitalisation rates for pneumonia in the six years following the introduction of PCV 7 23 
and 13. This should alleviate concerns regarding pneumococcal serotype replacement, as we have 24 
found no evidence of increased pneumonia burden in children following the introduction of PCV. We 25 
also observed a 33% reduction in the median length of stay in hospital for pneumonia in children 26 
aged below 2 years. However, we noted a dramatic and progressive increase in pneumonia 27 
hospitalisations in adults, most notably in those aged above 65 years. This translates to an annual 28 
increase of about 7000 hospital admissions for pneumonia across Scotland. This increase in hospital 29 
admissions is accompanied by contrasting decreases in the length of stay in hospital, the proportion 30 
of hospital admissions coded as pneumococcal pneumonia and pneumonia mortality in adults aged 31 
over 75 years.  32 
We found a gradual increase in the annual pneumonia hospitalisation rates for children aged below 33 
5 years in the pre-PCV period (Figure 1). These results are consistent with those reported in previous 34 
analyses of pneumonia trends in Scotland and England prior to the introduction of PCV [16, 17]. 35 
Koshy and colleagues concluded that this was likely due to a true increase in disease incidence 36 
(reflected in hospitalisation rates), as it was consistent with similar reports elsewhere.  37 
We reported a 30% decline in pneumonia hospitalisations in children aged below 2 years following 38 
the introduction of first PCV 7 and later PCV 13, which is reassuringly consistent with results of 39 
clinical trials investigating the effectiveness of PCV against radiographically confirmed WHO Primary 40 
Endpoint Pneumonia (bacterial) pneumonia [18, 19]. A previous study from England reported 19 to 41 
22 percent decline in hospitalisation rates for bacterial pneumonia in children aged below 15 years 42 
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in the two years post-PCV7 (2007 and 2008) [17].  Our results for the six years post-PCV in children 1 
aged below 18 years are consistent with those reported by Griffin and colleagues for US populations 2 
in the first decade after introduction of PCV 7 [14] (Panel 1).  3 
However, in older adults, our results contrast markedly from findings reported by Griffin and 4 
colleagues [14]. We estimated that in Scotland, the hospitalisation rate for all-cause pneumonia in 5 
adults aged 65-74 years in the post-PCV13 period was 640.4 per 100,000 persons per year compared 6 
to 376.6 per 100,000 persons per year in the pre-PCV period. Similar increases were seen in the age 7 
groups 75 years and above. By contrast, Griffin and colleagues reported a slight decrease in the rate 8 
of hospitalisation in the post-PCV7 period (1208 compared to 1293 per 100,000 persons per year) in 9 
the 65-74 year age group. More substantial decreases were reported in the older age groups (75 10 
years and above). In Scotland, this translates to an additional 7000 hospital admissions for 11 
pneumonia in post-PCV period, compared to 112,000 fewer hospitalisations in U.S adults. Griffin and 12 
colleagues attributed these declines to the indirect “herd immunity” effect of PCV on pneumococcal 13 
pneumonia. We did however observe a substantial decline in the proportion of pneumonia 14 
hospitalisations coded as pneumococcal disease across all age groups in the post-PCV period. 15 
However, it is very likely that we may have underestimated the impact of PCV on pneumococcal 16 
pneumonia. This is because hospital discharge data are based on clinical diagnoses recorded in 17 
patients’ medical records and accurate diagnosis of pneumococcal pneumonia is difficult without 18 
isolation of S. pneumoniae [20]. Notably, since 2010, we observed an increase in both the 19 
hospitalisations for pneumococcal pneumonia (numerator) and all-cause pneumonia (denominator) 20 
in adults older than 65 years even though there was a decrease in the proportion of pneumonia 21 
cases coded as pneumococcal pneumonia (Supplementary table 11). Extrapolating from the 22 
pneumonia hospitalisation rates in the pre-PCV period, we calculated the (expected) number of 23 
pneumonia hospitalisations assuming absence of PCV immunisation in the period 2007-12. Unlike in 24 
younger children, the expected number of pneumonia hospitalisations during this period would have 25 
been lower in older children (aged above 5 years) and adults. Therefore, it appears that the impact 26 
of child PCV immunization in Scotland on pneumonia hospitalisations has been limited to children 27 
aged younger than 5 years (Table 2). 28 
There are several reasons why our results are not consistent with those observed by Griffin and 29 
colleagues. Firstly, this could be attributed to differences in coding practices in both countries.  The 30 
US Nationwide Inpatient Sample (NIS) database uses up to 15 diagnostic positions, whereas ISD only 31 
uses up to 6 diagnostic positions. Therefore for a first diagnosis of meningitis, septicaemia or 32 
empyema, pneumonia could have been a secondary diagnosis in one of 14 diagnostic positions in 33 
the US study, but a secondary diagnosis in only one of 5 diagnostic positions in the present study. 34 
This could mean that fewer cases of septicaemia, meningitis and empyema were included as 35 
pneumonia cases in Scotland. It has been reported that during 2003-09 in the US there was an 36 
observed decrease in the coding for a primary diagnosis of pneumonia, which was partially 37 
compensated for by increases in coding for primary diagnoses of other diseases e.g. sepsis and 38 
respiratory failure [22]. Therefore, the decline in hospitalisations for pneumonia reported in the US 39 
may be partially due to an artefact of changes in diagnostic coding. In Scotland, the percentage of 40 
hospitalisations with pneumonia as a secondary diagnosis has remained almost static at 2.5% in the 41 
2000-2005 period, 2.4% in the 2007-2009 period and 2.5% in the 2010-2012 period. Although the 42 
study by Griffin and colleagues would have included cases with a primary diagnosis of sepsis as 43 
pneumonia hospitalisation, they would not have included diagnoses that were coded as respiratory 44 
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failure [14]. Indeed, Lindenauer and colleagues have reported that when combined with diagnoses 1 
of sepsis and respiratory failure, much more modest declines were seen in the hospitalisation rates 2 
for pneumonia [22]. Secondly, the US study was based on a 20% sample of US hospitals, whereas our 3 
study was based on inpatient data from the whole of Scotland. Thirdly, the increasing trend of adult 4 
pneumonia hospitalisations in Scotland may be an artefact of changing healthcare practices. This 5 
could have overcompensated for any declines in adult all-cause pneumonia hospitalisations that may 6 
have been seen as a result of the known herd effect of PCV [13]. Indeed, there was a 10 percent 7 
increase in all-cause hospitalisations (defined using CIS) during our study period (2000-2012) (data 8 
source: Information Services Division, National Services Scotland in response to data request IR2015-9 
01696). Fourthly, the increase in pneumonia hospitalisations could be attributed to improvement in 10 
coding practices (even though ICD-10 codes have been in use in Scotland since 1996).  Coding is also 11 
reported to have improved in England[23] and may have contributed to the apparent increases in 12 
pneumonia hospitalisations reported there [17].  In England and Wales, in the period 2000-10, there 13 
was an improvement in case ascertainment for invasive bacterial infections which is corroborated by 14 
a concomitant increase in cases of other invasive bacterial infections reported to Public Health 15 
England. Miller and colleagues corrected for these changes by retrospectively inflating the case 16 
count to the projected 2009-10 level of ascertainment [9]. They found that without adjusting for 17 
these changes there was little reported change in IPD incidence (across all age groups except 18 
children younger than 5 years) after PCV introduction although PCV has been demonstrated to have 19 
a substantial impact on IPD incidence both in children and adults [24].   20 
The National Audit Office (NAO) has reported an increasing trend of emergency hospital admissions 21 
in Scotland and the rest of the UK [25].  The increase was thought to be partially due to an ageing 22 
population and due to a tendency to treat patients as day cases or give patients earlier discharge to 23 
reduce bed pressure, resulting in more readmissions. This is consistent with our observation of a 24 
trend towards decreasing length of hospital stay for patients with pneumonia. In England there was 25 
a 40% increase in pneumonia hospitalisations for children aged less than 15 years between 1999 26 
through 2010 [26]. Moreover, another study from England has reported a 34% increase in hospital 27 
admissions for pneumonia before the introduction of PCV, mainly for pneumonias coded with an 28 
unspecified diagnosis [4]. Subsequent to changes to the general medical services contracts in 2004, 29 
General Practitioners in the UK (including Scotland) were no longer required to provide out of hours 30 
services. In England and Wales, this has resulted in a 32% increase in A&E attendances between 31 
2003-04 and 2013-14, translating into an 8% growth in the likelihood of being admitted to hospital 32 
after attending A&E during this period [27]. Indeed, patients may be more likely to be sent to 33 
hospital by an unfamiliar doctor [4]. This is likely to be true for Scotland as well. With increased 34 
emergency department visits and referrals there would be a greater diagnosis of pneumonias that 35 
would have otherwise gone undiagnosed. We also observed an overall increase in the percentage of 36 
hospital readmissions for pneumonia from 2.0% in 2000 to 3.6% in 2012. We therefore considered 37 
episodes generated from readmissions within 14 days to be part of the same event and 38 
consequently excluded them from our primary analysis. However, when disaggregated by age 39 
groups, we observed that the proportion of early readmissions (within 14 days of discharge) 40 
decreased in those younger than 40 years (the most substantial decrease of about 74 percent being 41 
in children aged below 2 years) (Supplementary table 9). The US study also found a trend of 42 
decreasing hospital stays before and after the introduction of PCV and found decreases in 43 
pneumonia hospitalisation rates, even without adjusting for readmissions [14].     44 
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The difference between our findings and those reported by Griffin cannot be attributed to 1 
differences in pneumococcal polysaccharide vaccine (PPV) coverage in the two populations as they 2 
are likely to be similar for Scotland and U.S. Limited PPV coverage data for Scotland are available − 3 
the initial vaccination uptake was estimated to be 65% [28]. Estimates for England indicate a 4 
coverage of about 69 percent [29]. Similarly, PPV was introduced in the US in 1997 for all individuals 5 
aged 65 years and above. Although recent coverage data are not available, the data for 2005 6 
estimate PPV coverage to be about 64 percent [30].  7 
Conclusions 8 
Our findings support the evidence on the impact of PCV on pneumonia hospitalisations in children, 9 
indicating that vaccine impact in this national programme is broadly consistent with predictions from 10 
vaccine trials. It is reassuring that reductions in hospitalization have persisted over 6 years with no 11 
evidence of negative indirect effects (due to serotype replacement) eroding this impact over this 12 
time period. This reduced proportion of pneumonia hospitalisations in children coded as 13 
pneumococcal disease post PCV13 introduction gives further reassurance that there is not a 14 
substantial serotype replacement effect over the study period. The failure to note any positive 15 
indirect effect of infant PCV vaccination on (pneumococcal) pneumonia in non-vaccinated individuals 16 
observed through measurement of hospitalisations among older individuals is likely due to 17 
contemporaneous changes in clinical practice and coding as discussed above. This suggests that 18 
indirect effects of PCV on observed hospitalisations may be context specific and demonstrates that 19 
health care planners and health economists cannot, with confidence, predict positive indirect PCV 20 
vaccine impacts on hospitalisations in their estimates of vaccine impact on health service costs. IPD 21 
surveillance in all age groups is needed to assess the indirect effects of PCV in the community.   22 
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Figure title and legends 
Figure 1: Pneumonia hospitalisations in Scotland from July 2000 to June 2012 in children. Panel A 
shows annual rates of hospitalisation for pneumonia from 2000 through 2012. PCV 7 was introduced 
in 2006 and PCV 13 in 2010. Panel B shows annual rates of hospitalisation for 2000 to 2005, 2007 to 
2009 and 2010 to 2012 for all children (including those coded as “other” health boards) 
 
Figure 2: Pneumonia hospitalisations in Scotland from July 2000 to June 2012 in adults. Panel A 
shows annual rates of hospitalization for pneumonia from 2000 through 2012. PCV 7 was introduced 
in 2006 and PCV 13 in 2010. Panel B shows annual rates of hospitalization for 2000 to 2005, 2007 to 
2009 and 2010 to 2012 for all adults (including those coded as “other” health boards) 
 
Figure 3: Average Annual Rates of Scottish hospitalisations for Pneumonia before and after the 
introduction of PCV7 and PCV13  
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Table 1: Rates of hospitalisation, length of hospital stay, and rates of in-hospital death related to pneumonia in Scotland 5 years before introduction of PCV 7 and three years after introduction 
of PCV 13 
Age (years) <2 2-4 5-17 18-39 40-64 65-74 75-84 85+ 
Pneumonia Hospitalisation 
rate /100K* 
(95% CI) 
        
2000-2005 293 
(280-306) 
181 
(173-190) 
43 
(41-45) 
53 
(51-54) 
112 
(110-114) 
373 
(365-380) 
875 
(861-889) 
1909 
(1872-1946) 
2010-2012 206 
(191-221) 
177 
(166-188) 
45 
(42-48) 
62 
(59-64) 
182 
(179-186) 
634 
(621-647) 
1426 
(1402-1451) 
2785 
(2728-2842) 
         
Lengths of hospital stay 
(days). Median (IQR) 
        
2000-2005 3 (1-5) 2 (1-4) 3 (1-5) 4 (2-6) 5 (3-10) 7 (4-14) 9 (4-19) 11 (5-25) 
2010-2012 2 (1-5) 2 (1-4) 2 (1-5) 3 (1-6) 5 (2-9) 6 (3-12) 7 (4-15) 9 (4-19) 
         
Lengths of hospital stay 
(days) incl. readmissions 
within 14 days. Median, IQR 
        
2000-2005 3 (1-5) 2 (1-4) 3 (1-5) 4 (2-7) 5 (3-11) 7 (4-15) 9 (4-20) 12 (4-25) 
2010-2012 2 (1-5) 2 (1-4) 2 (1-5) 3 (1-7) 5 (2-9) 6 (3-12) 8 (4-16) 9 (4-19) 
         
Reasons for admission 
coded as pneumococcal 
disease. %, 95% CI 
        
2000-2005 9.3  
(8.1-10.7) 
3.3 
(2.5-4.2) 
4.1  
(3.4-5.1) 
6.8 
(6.1-7.5) 
6.1  
(5.7-6.6) 
3.8 
(3.4-4.1) 
2.3  
(2.0-2.5) 
1.1 
(1.0-1.4) 
2010-2012 3.3  
(2.3, 4.9) 
1.1  
(0.6-1.9) 
2.5  
(1.7-3.6) 
3.5  
(2.9-4.3) 
2.9  
(2.6-3.3) 
1.7  
(1.4-2.0) 
1.0  
(0.8-1.2) 
0.7 
(0.5-0.9) 
         
                                                          
* The hospitalisation rates have been calculated after excluding data where patient’s health board was coded as “other” 
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Age (years) <2 2-4 5-17 18-39 40-64 65-74 75-84 85+ 
Deaths from pneumonia 
(primary cause, all 
patients)† %, 95% CI 
        
2000-2005 0 0.06 (0.008, 
0.4) 
0.2 (0.1, 0.6) 0.7 (0.5, 1.0) 3.5 (3.2, 3.8) 6.9 (6.5, 7.4) 13.1 (12.5, 
13.6) 
25.8 (24.9, 
26.6) 
2010-2012 0 0 0.3 (0.1, 0.9) 0.3 (0.1, 0.6) 1.4 (1.2, 1.7) 3.4 (3.0, 3.7) 6.2 (5.8, 6.6) 15.7 (15.0, 
16.5) 
         
Deaths from pneumonia as 
proportion of all deaths 
(primary cause)‡ %, 95% CI 
        
2000-2005 0 2.4 (0.3, 
15.1) 
3.1 (1.3, 7.4) 5.2 (3.7, 7.2) 7.4 (6.7, 8.2) 8.7 (8.1, 9.3) 14.1 (13.5, 
14.7) 
26.3 (25.4, 
27.2) 
2010-2012 0 0 11.1 (3.6, 
29.3) 
4.3 (2.2, 8.4) 6.0 (5.1, 7.1) 8.2 (7.4, 9.2) 12.0 (11.2, 
12.8) 
24.0 (22.9, 
25.1) 
         
Deaths from pneumonia 
(any cause, all patients)§ %, 
95% CI 
        
2000-2005 0.8 (0.5, 1.3) 0.6 (0.3, 1.0) 2.3 (1.8, 3.0) 3.7 (3.2, 4.3) 18.8 (18.1, 
19.5) 
36.9 (35.9, 
37.8) 
52.8 (52.0, 
53.6) 
66.1 (56.1, 
67.0) 
2010-2012 0.7 (0.3, 1.6) 0.2 (0.05, 
0.8) 
2.1 (1.4, 3.2) 2.4 (1.9, 3.1) 8.5 (8.0, 9.1) 14.9 (14.2, 
15.6) 
21.6 (20.9, 
22.3) 
36.1 (35.1, 
37.1) 
                                                          
† Deaths with pneumonia as a primary cause as a proportion of the whole population 
‡ Deaths with pneumonia as a primary cause as a proportion of the deaths reported in this population 
§ Deaths with pneumonia as any cause as a proportion of the whole population 
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Table 2: Difference in Pneumonia Hospitalisation Rates in Scotland Comparing pre-PCV7 and post-PCV13 Periods. With Absolute Change in Hospitalisations by 2012 
Age group Pneumonia 
Hospitalisations 
in 2012 
Scottish 
Population 2012 
Difference in 
hospitalisation rates 
per 100,000 
population, PrePCV7 
vs LatePCV7/PCV13 (n, 
95% CI) 
Difference in 
Hospitalisations, 
PrePCV7 to Late 
PCV7/PCV13 
(%, 95% CI)1 
Expected number of 
hospitalisations from 
2000-2006 
distribution2 
Estimated Absolute 
Change in Number of 
Hospitalisations, 2012 
(observed – expected), 
n, 95% CI 
<2 240 119,275 -87.0 (-107.0, -67.0) -29.7 (-36.5, -22.8) 349.8 -109.8 (-125.7, -94.0) 
2-4 283 176,596 -4.8 (-19.0, 9.0) -2.8 (-10.5, 5.1) 320.9 -37.9 (-52.7, -23.0) 
5-17 262 742,593 2.1 (-1.0, 5.4) 4.9 (-2.3, 12.6) 317.8 -55.8 (-69.9, -42.5) 
18-39 783 1,506,987 9.1 (6.4, 11.9) 17.4 (12.2, 22.7) 789.7 -6.7 (-29.3, 15.9) 
40-64 3521 1,842,398 70.3 (66.2, 74.4) 62.9 (59.2, 66.6) 2058.0 1463.0 (1424.4, 1500.0) 
65-74 3467 507,265 262.0 (247.2, 276.7) 70.4 (66.4, 74.3) 1888.5 1578.5 (1541.4, 1615.5) 
75-84 4888 309,244 551.6 (523.4, 579.7) 63.0 (59.8, 66.3) 2705.6 2182.4 (2138.8, 2226.0) 
85+ 3372 109,242 876.4 (808.7, 944.1) 45.9 (42.4, 49.5) 2085.4 1286.6 (1246.2, 1327.0) 
All Ages 16816 5,313,600 110.3 (107.2, 113.3) 59.6 (57.9, 61.2) 9835.5 6980.5 (6895.5, 7060.2) 
1 As percentage of 2000-2006 (PrePCV7) data 
2 Derived from hospitalisation rate from PrePCV7 data applied to the 2012 population figures
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